Miguel Munoz

Summary

Affiliation: Instituto de la Grasa
Country: Spain

Publications

  1. ncbi The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug
    Miguel Munoz
    Research Laboratory on Neuropeptides, Virgen del Rocío University Children s Hospital, Sevilla, Spain
    Invest New Drugs 28:187-93. 2010
  2. ncbi Neurokinin-1 receptor: a new promising target in the treatment of cancer
    Miguel Munoz
    Research Laboratory on Neuropeptides, Hospital Infantil Universitario Virgen del Rocio, Sevilla 41013, Spain
    Discov Med 10:305-13. 2010
  3. ncbi The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines
    Miguel Munoz
    Research Laboratory on Neuropeptides, Virgen del Rocio University Hospital, Sevilla, Spain
    Invest New Drugs 30:529-40. 2012
  4. ncbi Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines
    Miguel Munoz
    Hospital Infantil Universitario Virgen del Rocio, Sevilla, Spain
    Melanoma Res 14:183-8. 2004
  5. ncbi NK-1 receptor antagonists: a new paradigm in pharmacological therapy
    M Munoz
    Hospital Infantil Universitario Virgen del Rocio, Unidad de Cuidados Intensivos Pediatricos, Sevilla, Spain
    Curr Med Chem 18:1820-31. 2011
  6. ncbi The NK-1 receptor: a new target in cancer therapy
    Miguel Munoz
    Research Laboratory on Neuropeptides, Virgen del Rocio University Hospital, Sevilla, Spain
    Curr Drug Targets 12:909-21. 2011
  7. ncbi The broad-spectrum antitumor action of cyclosporin A is due to its tachykinin receptor antagonist pharmacological profile
    Miguel Munoz
    Virgen del Rocío University Children s Hospital, Sevilla, Spain
    Peptides 31:1643-8. 2010
  8. ncbi The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines
    Miguel Munoz
    Research Laboratory on Neuropeptides, Virgen del Rocio University Hospital, Sevilla, Spain
    Lab Invest 90:1259-69. 2010
  9. ncbi Immunolocalization of NK-1 receptor and Substance P in human normal placenta
    M Munoz
    Research Laboratory on Neuropeptides, Virgen del Rocío University Children s Hospital, Sevilla, Spain
    Placenta 31:649-51. 2010
  10. ncbi A new frontier in the treatment of cancer: NK-1 receptor antagonists
    M Munoz
    Research Laboratory on Neuropeptides, Virgen del Rocio University Hospital, Sevilla, Spain
    Curr Med Chem 17:504-16. 2010

Collaborators

Detail Information

Publications17

  1. ncbi The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug
    Miguel Munoz
    Research Laboratory on Neuropeptides, Virgen del Rocío University Children s Hospital, Sevilla, Spain
    Invest New Drugs 28:187-93. 2010
    ..These findings reported here for the first time indicate that aprepitant is a new and promising broad spectrum antitumor drug in the treatment of cancer...
  2. ncbi Neurokinin-1 receptor: a new promising target in the treatment of cancer
    Miguel Munoz
    Research Laboratory on Neuropeptides, Hospital Infantil Universitario Virgen del Rocio, Sevilla 41013, Spain
    Discov Med 10:305-13. 2010
    ....
  3. ncbi The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines
    Miguel Munoz
    Research Laboratory on Neuropeptides, Virgen del Rocio University Hospital, Sevilla, Spain
    Invest New Drugs 30:529-40. 2012
    ..These findings suggest that NK-1 receptor antagonists could be considered as new antitumor drugs for the treatment of human ALL...
  4. ncbi Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines
    Miguel Munoz
    Hospital Infantil Universitario Virgen del Rocio, Sevilla, Spain
    Melanoma Res 14:183-8. 2004
    ..This action, shown here for the first time, suggests that the NK1 receptor antagonist L-733 060 could be a promising therapeutic drug in the treatment of the human melanoma...
  5. ncbi NK-1 receptor antagonists: a new paradigm in pharmacological therapy
    M Munoz
    Hospital Infantil Universitario Virgen del Rocio, Unidad de Cuidados Intensivos Pediatricos, Sevilla, Spain
    Curr Med Chem 18:1820-31. 2011
    ..In this review, we update the multiple therapeutic effects exerted by NK-1 receptor antagonists...
  6. ncbi The NK-1 receptor: a new target in cancer therapy
    Miguel Munoz
    Research Laboratory on Neuropeptides, Virgen del Rocio University Hospital, Sevilla, Spain
    Curr Drug Targets 12:909-21. 2011
    ..In sum, the NK-1 receptor may be a new and promising target in the treatment of human cancer...
  7. ncbi The broad-spectrum antitumor action of cyclosporin A is due to its tachykinin receptor antagonist pharmacological profile
    Miguel Munoz
    Virgen del Rocío University Children s Hospital, Sevilla, Spain
    Peptides 31:1643-8. 2010
    ....
  8. ncbi The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines
    Miguel Munoz
    Research Laboratory on Neuropeptides, Virgen del Rocio University Hospital, Sevilla, Spain
    Lab Invest 90:1259-69. 2010
    ..These findings show for the first time that the NK-1 receptor may be a promising new target and that the NK-1 receptor antagonist aprepitant could be a candidate as a new antitumor drug in the treatment of human melanoma...
  9. ncbi Immunolocalization of NK-1 receptor and Substance P in human normal placenta
    M Munoz
    Research Laboratory on Neuropeptides, Virgen del Rocío University Children s Hospital, Sevilla, Spain
    Placenta 31:649-51. 2010
    ..The SP is located in both the cytoplasm and the nucleus whereas NK-1 receptor in cytoplasmic. These findings reported here for the fist time, suggest a role for the SP and NK-1 receptor in the placental physiology...
  10. ncbi A new frontier in the treatment of cancer: NK-1 receptor antagonists
    M Munoz
    Research Laboratory on Neuropeptides, Virgen del Rocio University Hospital, Sevilla, Spain
    Curr Med Chem 17:504-16. 2010
    ....
  11. ncbi NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2
    Miguel Munoz
    Hospital Universitario Virgen del Rocio, Seville, Spain
    Invest New Drugs 26:111-8. 2008
    ..This new action, reported here for the first time, suggests that the NK-1 receptor is a new and promising target in the treatment of human laryngeal carcinoma...
  12. ncbi Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138
    Miguel Munoz
    Pediatric Intensive Care Unit, Virgen del Rocío University Children s Hospital, Sevilla, Spain
    Invest Ophthalmol Vis Sci 48:2775-81. 2007
    ..The authors also sought to demonstrate that the administration of L-732,138 or L-733,060 induces apoptosis in retinoblastoma cells and that neurokinin-1 receptors and substance P are present in primary retinoblastoma...
  13. ncbi Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines
    Miguel Munoz
    Hospital Universitario Virgen del Rocio, Sevilla, Spain
    Invest Ophthalmol Vis Sci 46:2567-70. 2005
    ..The ability of substance P (an neurokinin-1 stimulator) to activate the cell growth of these retinoblastoma cell lines was also determined...
  14. ncbi The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines
    M Munoz
    Hospital Infantil Universitario Virgen del Rocio, Unidad de Cuidados Intensivos Pediatricos, Av Manuel Siurot S N, 41013 Sevilla, Spain
    Neuropeptides 39:427-32. 2005
    ..This action suggests that the NK1 receptor is a new and promising target in the treatment of human neuroblastoma and glioma...
  15. ncbi Antitumoural action of L-733,060 on neuroblastoma and glioma cell lines
    M Munoz
    Hospital Infantil Universitario Virgen del Rocio, Sevilla, Spain
    Arch Ital Biol 142:105-12. 2004
    ..This new action, reported here for the first time, suggests that the NK1 receptor antagonist L-733,060 could be a promising therapeutic drug for the treatment of human neuroblastoma and human glioma...
  16. ncbi NK-1 as a melanoma target
    Miguel Munoz
    Hospital Infantil Universitario Virgen del Rocio, Unidad de Cuidados Intensivos Pediatricos, Research Laboratory on Neuropeptides, Sevilla, Spain
    Expert Opin Ther Targets 15:889-97. 2011
    ..This should be faster compared with less investigated NK-1 receptor antagonists, because a great part of the required safety and characterization studies for aprepitant have already been carried out...
  17. ncbi The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines
    Marisa Rosso
    Virgen del Rocío University Children s Hospital, Sevilla, Spain
    Tumour Biol 29:245-54. 2008
    ..At present, it is unknown whether such actions are exerted on human gastric and colon adenocarcinomas. We carried out an in vitro study of the growth-inhibitory capacity of L-733,060 against human gastric and colon adenocarcinomas...